Glenmark Pharmaceuticals Out-Licenses Anti-Inflammatory Antibody to Sanofi-aventis
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 5 (Table of Contents)
Published: 23 May-2011
DOI: 10.3833/pdr.v2011.i5.1474 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In the largest out-licensing deal to date by an emerging market company, Glenmark Pharmaceuticals has entered into an agreement with Sanofi-aventis, potentially worth US$613 M, for the development and commercialisation of its first-in-class anti-inflammatory monoclonal antibody drug candidate, GBR 500...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS